Non-arteritic anterior ischemic optic neuropathy (NAION) is a vision-related drug side effect commonly referred to as an “eye stroke”. In this post, we focus on a new Ozempic eye stroke side effect rates study published in the March 2026 British Journal of Ophthalmology article, “Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk“.
In part, that March 2026 medical journal article presents two new facts concerning the incidence rate of this Ozempic NAION / eye stroke side effect:
(1) The Wegovy (another semaglutide-containing drug) and Ozempic eye stroke side effect was diagnosed in men three times more than in women.
(2) The Wegovy eye stroke side effect rate is five times that of Ozempic.
Earlier Drug Injury Law Posts About
Ozempic Eye Stroke Side Effect
As background for this Wegovy and Ozempic eye stroke side effect rate study published in March 2026, here is a list of some earlier posts from our Drug Injury Law website about non-arteritic anterior ischemic optic neuropathy (NAION) associated with Wegovy and Ozempic, as well as Rybelsus, all three being the semaglutide-containing drugs from the pharmaceutical company Novo Nordisk:
- Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
- Ozempic Vision Loss Claims Compensation Payments Made in 2025
- Ozempic NAION Rate Higher in Recent 2025 Medical Study
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
We have been following the Ozempic eye stroke side effect since July 2024. During that time, we have investigated possible drug injury lawsuits against Novo Nordisk for patients diagnosed with an eye stroke, or NAION, and suffered vision loss.
If you have a possible NAION drug injury lawsuit involving one of the semaglutide drugs from Novo Nordisk that you want reviewed, you can submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online, send an email to TJL@LambLawOffice.com, or call us at 910-256-2971.
Ozempic / Wegovy / Rybelsus
Free Case Evaluation
Strictly Confidential, No Obligation